REVCOVI
Drug
Chiesi USA, Inc.
Total Payments
$788,966
Transactions
97
Doctors
31
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $47,506 | 17 | 11 |
| 2023 | $514,964 | 34 | 6 |
| 2022 | $175,938 | 29 | 9 |
| 2021 | $50,559 | 17 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $687,845 | 45 | 87.2% |
| Honoraria | $51,107 | 13 | 6.5% |
| Grant | $30,000 | 1 | 3.8% |
| Consulting Fee | $14,308 | 10 | 1.8% |
| Travel and Lodging | $3,520 | 7 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,434 | 2 | 0.2% |
| Food and Beverage | $752.56 | 19 | 0.1% |
Payments by Type
Research
$687,845
45 transactions
General
$101,121
52 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RegistryStudyofRevcoviTreatment in Patients With ADA-SCID | Chiesi USA, Inc. | $440,845 | 0 |
| Monitoring Enzyme Replacement Therapy (Registry Surveillance Study) | Leadiant Biosciences, Inc. | $30,658 | 0 |
Top Doctors Receiving Payments for REVCOVI — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Clinical Genetics (M.D.) | Phoenix, AZ | $19.26 | 1 |
| , PNP | Pediatrics | Phoenix, AZ | $19.26 | 1 |
| , MD | Clinical Genetics (M.D.) | Phoenix, AZ | $19.26 | 1 |
| , M.D | Pediatrics | Phoenix, AZ | $19.26 | 1 |
| , M.D., | Pediatric Allergy/Immunology | Miami Lakes, FL | $18.63 | 1 |
| , D.O | Pediatric Allergy/Immunology | Miami Lakes, FL | $18.63 | 1 |
| , MD | Pediatric Allergy/Immunology | Dayton, OH | $18.63 | 1 |
Ad
Manufacturing Companies
- Chiesi USA, Inc. $541,966
- CHIESI USA, INC. $216,342
- Leadiant Biosciences, Inc. $30,658
Product Information
- Type Drug
- Total Payments $788,966
- Total Doctors 31
- Transactions 97
About REVCOVI
REVCOVI is a drug associated with $788,966 in payments to 31 healthcare providers, recorded across 97 transactions in the CMS Open Payments database. The primary manufacturer is Chiesi USA, Inc..
Payment data is available from 2021 to 2024. In 2024, $47,506 was paid across 17 transactions to 11 doctors.
The most common payment nature for REVCOVI is "Unspecified" ($687,845, 87.2% of total).
REVCOVI is associated with 2 research studies, including "RegistryStudyofRevcoviTreatment in Patients With ADA-SCID" ($440,845).